menu
    • menu

    Company profile for Immunogen

    NEW Drugs in Dev: 9
    Abbvie Contract Manufacturing-PSE
    News
    ImmunoGen`s Biologics Elahere Receives Suppl Approval in US

    14 Jul 2025

    // FDA

    Zydus, Gates Foundation To Develop Shigellosis-Typhoid Vaccine

    04 Mar 2025

    // INDPHARMAPOST

    Valneva Reports Positive Phase 2 Chikungunya Vaccine Results

    22 Jan 2025

    // GLOBENEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    Immunogen

    Contact Supplier

    Website

    34th NZW-Hamburg

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    radio-compass-blog/top-news-of-2025-drugmakers-invest-in-us-capacities-agree-to-lower-medicaid-prices-pfizer-buys-obesity-focused-biotech-metsera

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Targeting a better life for people with cancer is why we get up in the morning. It’s not enough to disrupt the progress of someone’s cancer; we want to keep cancer from disrupting someone’s life. That’s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives – back to living today, tomorrow, and beyond. For us, targeting a better now is the only thing that matters.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmunogenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    830 Winter Street Waltham, MA 02451-1477
    Telephone
    Telephone
    781-895-0600
    Client Email
    Email
    info@immunogen.com
    Client Website
    Website
    https://www.immunogen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immunogen-inc.
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    34th NZW-Hamburg

    Not Confirmed

    envelop Contact Supplier

    34th NZW-Hamburg

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    ImmunoGen`s Biologics Elahere Receives Suppl Approval in US
    ImmunoGen`s Biologics Elahere Receives Suppl Approval in US

    14 Jul 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761310

    FDA
    14 Jul 2025
    Share Share
    Zydus, Gates Foundation To Develop Shigellosis-Typhoid Vaccine
    Zydus, Gates Foundation To Develop Shigellosis-Typhoid Vaccine

    04 Mar 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/zydus-and-gates-foundation-to-develop-worlds-first-combination-vaccine-to-offer-protection-against-shigellosis-and-typhoid-16850

    INDPHARMAPOST
    04 Mar 2025
    Share Share
    Valneva Reports Positive Phase 2 Chikungunya Vaccine Results
    Valneva Reports Positive Phase 2 Chikungunya Vaccine Results

    22 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/22/3013729/0/en/Valneva-Reports-Positive-Phase-2-Results-in-Children-for-its-Chikungunya-Vaccine-and-Announces-Phase-3-Dose-Decision.html

    GLOBENEWSWIRE
    22 Jan 2025
    Share Share
    PopVax Wins $2M BARDA Prize For Flu Vaccine Using Microarray Patch
    PopVax Wins $2M BARDA Prize For Flu Vaccine Using Microarray Patch

    13 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250113384141/en

    BUSINESSWIRE
    13 Jan 2025
    Share Share
    Nature Highlights Stratis® DNA Vaccine For Hantaviruses
    Nature Highlights Stratis® DNA Vaccine For Hantaviruses

    10 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210862815/en

    BUSINESSWIRE
    10 Dec 2024
    Share Share
    Vaxcyte Starts Phase 2 Study of VAX-31 in Infants
    Vaxcyte Starts Phase 2 Study of VAX-31 in Infants

    03 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/03/2990544/0/en/Vaxcyte-Initiates-Phase-2-Study-Evaluating-VAX-31-for-the-Prevention-of-Invasive-Pneumococcal-Disease-in-Infants.html

    GLOBENEWSWIRE
    03 Dec 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Check the ref. standards & impurities from this company

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search